Skip to main content
Top
Published in: Advances in Therapy 5/2024

Open Access 04-04-2024 | Wilson's Disease | Original Research

Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research

Authors: Stella Karantzoulis, Karli Heuer, Nicole Sparling, Brian Meltzer, Megan Teynor

Published in: Advances in Therapy | Issue 5/2024

Login to get access

Abstract

Introduction

Wilson disease (WD) is a rare metabolic disorder of impaired copper transport manifesting in hepatic, neurological, and psychiatric symptoms. To evaluate the clinical symptoms of WD in clinical trials, a group of clinicians created the Unified Wilson Disease Rating Scale (UWDRS). Content validity of this scale has not been established. The aim of this study was to evaluate the content validity of the UWDRS Part II from the patient perspective.

Methods

This study utilized multiple qualitative research methods including concept elicitation interviews, concept/instrument mapping, and cognitive debriefing interviews.

Results

Concept elicitation interviews with a sample of patients with WD and one or more neurological signs/symptoms identified several signs, symptoms, and impacts related to neurological dysfunction, strengthening our understanding of the importance of the neurological aspects of the WD patient experience. Mapping neurological concepts to Part II and III items of the UWDRS showed complete coverage of all salient neurological concepts and near complete coverage of all neurological concepts reported by patients in concept elicitation interviews. Item debriefing of Part II of the UWDRS revealed that patients generally found the items clear and personally relevant to their experience with WD.

Conclusion

Overall, the findings from this study provide evidence for the content validity of the UWDRS Part II and supportive evidence for the content validity of Part III. The UWDRS should be used in conjunction with additional clinical outcomes assessments, specifically those evaluating the hepatic and psychiatric signs/symptoms of WD, to provide a comprehensive evaluation of the WD patient experience.
Appendix
Available only for authorised users
Literature
2.
go back to reference Członkowska A, Tarnacka B, Möller JC, et al. Unified Wilson‘s disease rating scale - a proposal for the neurological scoring of Wilson’s disease patients. Neurol Neurochir Pol. 2007;41(1):1–12.PubMed Członkowska A, Tarnacka B, Möller JC, et al. Unified Wilson‘s disease rating scale - a proposal for the neurological scoring of Wilson’s disease patients. Neurol Neurochir Pol. 2007;41(1):1–12.PubMed
5.
go back to reference Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1–eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77. https://doi.org/10.1016/j.jval.2011.06.014.CrossRefPubMed Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1–eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77. https://​doi.​org/​10.​1016/​j.​jval.​2011.​06.​014.CrossRefPubMed
9.
go back to reference Reilly M, Daly L, Hutchinson M. An epidemiological study of Wilson’s disease in the Republic of Ireland. J Neurol Neurosurg Psychiatry. 1993;56(3):298–300.CrossRefPubMedPubMedCentral Reilly M, Daly L, Hutchinson M. An epidemiological study of Wilson’s disease in the Republic of Ireland. J Neurol Neurosurg Psychiatry. 1993;56(3):298–300.CrossRefPubMedPubMedCentral
Metadata
Title
Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research
Authors
Stella Karantzoulis
Karli Heuer
Nicole Sparling
Brian Meltzer
Megan Teynor
Publication date
04-04-2024
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 5/2024
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-024-02833-w

Other articles of this Issue 5/2024

Advances in Therapy 5/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine